RxDoctor Payments DataLook up a doctor →

Jose Luciano, MD

Critical Care Medicine · Saint Petersburg, FLNPI 1578640876

Payments from drug & device makers

$76,009in general payments, 2019–2025

Across 571 payments — averaging $133.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$62K
  • Pfizer$3K
  • AstraZeneca$2K
  • GSK$1K
  • Boehringer Ingelheim$944
  • Insmed, Inc.$900
  • plus $6K from 43 others

What the payments were for

  • Food & beverage$11,46499%
  • Education$1141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$76,009 in reported general payments places this provider in the 90th percentile of 618 critical care medicine providers in Florida.

See all critical care medicine providers in Florida

Medicare billing

Part B allowed, 2024
$196,223
Medicare patients
489
Services billed
1,530

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AdempasRiociguat38$553,657
Orenitram ErTreprostinil Diolamine36$488,771
OfevNintedanib Esylate24$214,846
ArikayceAmikacin Liposomal/Neb.Accessr12$187,265
OpsumitMacitentan12$151,198
Trelegy ElliptaFluticasone/Umeclidin/Vilanter73$93,580
Breztri AerosphereBudesonide/Glycopyr/Formoterol57$81,306
NucalaMepolizumab21$76,177
TezspireTezepelumab-Ekko11$49,742
Stiolto RespimatTiotropium Br/Olodaterol Hcl24$19,819
Breo ElliptaFluticasone/Vilanterol12$11,522
SymbicortBudesonide/Formoterol Fumarate17$7,200
Albuterol Sulfate HfaAlbuterol Sulfate94$3,668
Roflumilast21$2,704
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$2,453

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerAdempas$423$553,65738 claims
Boehringer IngelheimOfev, Stiolto Respimat$944$234,66448 claims
Insmed, Inc.Arikayce$900$187,26512 claims
GSKTrelegy Ellipta, Nucala, Breo Ellipta$1,500$181,279106 claims
Actelion Pharmaceuticals US, Inc.Opsumit$840$151,19812 claims
AstraZenecaBreztri Aerosphere, Tezspire, Symbicort$2,175$138,24985 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 618 critical care medicine providers in Florida.

Other critical care medicine in Saint Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →